Xeris Pharmaceuticals Inc (XERS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 121,747 | 111,750 | 111,042 | 91,598 | 59,285 |
| Receivables | 58,105 | 56,295 | 51,050 | 53,751 | 53,048 |
| Inventories | 80,930 | 74,234 | 68,673 | 67,462 | 67,282 |
| TOTAL | $274,757 | $251,682 | $240,313 | $224,017 | $185,578 |
| Non-Current Assets | |||||
| PPE Net | 4,834 | 5,033 | 4,945 | 4,946 | 5,284 |
| Intangibles | 105,516 | 108,227 | 110,937 | 113,648 | 116,359 |
| Other Non-Current Assets | 26,798 | 27,071 | 27,332 | 27,580 | 27,465 |
| TOTAL | $137,148 | $140,331 | $143,214 | $146,174 | $149,108 |
| Total Assets | $411,905 | $392,013 | $383,527 | $370,191 | $334,686 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 63,783 | N/A | 0 | 0 | 0 |
| Accounts payable and accrued liabilities | 9,337 | 11,467 | 3,076 | 6,527 | 9,462 |
| Accrued Expenses | 65,456 | 64,215 | 62,222 | 70,480 | 52,951 |
| Other current liabilities | 4,976 | 4,353 | 4,889 | 2,649 | 1,633 |
| TOTAL | $189,568 | $118,593 | $109,574 | $116,200 | $95,171 |
| Non-Current Liabilities | |||||
| Long Term Debt | 188,807 | 221,224 | 220,335 | 219,469 | 218,626 |
| Other Non-Current Liabilities | 43,264 | 39,185 | 39,929 | 35,383 | 40,193 |
| TOTAL | $232,071 | $260,409 | $260,264 | $254,852 | $258,819 |
| Total Liabilities | $421,639 | $379,002 | $369,838 | $371,052 | $353,990 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 182,320 | 172,642 | 172,431 | 165,924 | 161,480 |
| Common Shares | 18 | 18 | 17 | 17 | 16 |
| Retained earnings | -700,174 | -669,073 | -671,307 | -682,388 | -683,009 |
| Other shareholders' equity | -10 | -24 | -25 | -25 | -24 |
| TOTAL | $-9,734 | $13,011 | $13,689 | $-861 | $-19,304 |
| Total Liabilities And Equity | $411,905 | $392,013 | $383,527 | $370,191 | $334,686 |